Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 203

Similar articles for PubMed (Select 19402858)

1.

Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.

Pullan PT.

Intern Med J. 2009 Apr;39(4):213-5. doi: 10.1111/j.1445-5994.2009.01916.x. No abstract available.

PMID:
19402858
2.

Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.

Senol MG, Togrol RE.

Neurology. 2007 Jul 3;69(1):117; author reply 117-8. No abstract available.

PMID:
17606893
3.

Dopamine agonists and the risk of cardiac-valve regurgitation.

Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E.

N Engl J Med. 2007 Jan 4;356(1):29-38.

4.

Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

Cardiovasc Ther. 2011 Dec;29(6):404-10. doi: 10.1111/j.1755-5922.2010.00169.x. Epub 2010 Jun 11.

PMID:
20553285
5.

Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.

Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E.

Clin Neurol Neurosurg. 2007 May;109(4):350-3. Epub 2007 Feb 20.

PMID:
17307289
6.

Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

N Engl J Med. 2007 Jan 4;356(1):39-46.

7.

Drugs and valvular heart disease.

Roth BL.

N Engl J Med. 2007 Jan 4;356(1):6-9. No abstract available.

PMID:
17202450
8.
9.

Cardiopulmonary complications of ergot-derivative dopamine agonists.

Rack MJ, Baran AS, Richert AC, Roffwarg HP.

J Clin Psychiatry. 2004 Oct;65(10):1429-30; author reply 1430. No abstract available.

PMID:
15491249
10.

The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.

Ooba N, Yamaguchi T, Kubota K.

Drug Saf. 2011 Apr 1;34(4):329-38. doi: 10.2165/11588230-000000000-00000.

PMID:
21417505
11.

[Cabergoline in hyperprolactinemia and valvular heart disease].

Vargas ML, Cervantes CE, Hernando CA, Da Costa CV.

Endocrinol Nutr. 2009 Oct;56(8):412-7. doi: 10.1016/S1575-0922(09)72711-1. Review. Spanish.

PMID:
19959151
12.

Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.

Simonis G, Fuhrmann JT, Strasser RH.

Mov Disord. 2007 Oct 15;22(13):1936-42.

PMID:
17659636
14.

Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.

Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P.

Mov Disord. 2004 Dec;19(12):1522-3. No abstract available.

PMID:
15515009
15.

Pergolide in Parkinson's disease: time for a change?

Grosset KA, Grosset DG.

Lancet. 2004 Jun 5;363(9424):1907-8. No abstract available.

PMID:
15183636
16.

Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.

Trifirò G, Morgante L, Tari M, Arcoraci V, Savica R.

J Am Geriatr Soc. 2008 Feb;56(2):371-3. doi: 10.1111/j.1532-5415.2007.01522.x. No abstract available.

PMID:
18251828
17.

Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.

Sherlock M, Toogood AA, Steeds R.

Heart. 2009 Apr;95(7):522-3. doi: 10.1136/hrt.2008.163345. Epub 2009 Jan 27. No abstract available.

PMID:
19174419
18.

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

Antonini A, Poewe W.

Lancet Neurol. 2007 Sep;6(9):826-9. Review.

PMID:
17706566
19.

Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.

Bares M, Rektorová I, Krajcovicová L, Rektor I.

J Neurol. 2008 Oct;255(10):1596; author reply 1597. doi: 10.1007/s00415-008-0972-x. Epub 2008 Sep 3. No abstract available.

PMID:
18758889
20.

[Cardiac valvulopathy and dopamine agonist].

Grandas F.

Neurologia. 2007 Dec;22(10):870-81. Review. Spanish.

PMID:
17671852
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk